The Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-α Inadequate Response Mechanisms.
Jing WangMichael MacorittoHeath GuayJustin W DavisMarc C LevesqueXiaohong CaoPublished in: Inflammatory bowel diseases (2022)
Collectively, these data suggest that upadacitinib and risankizumab affect TNF-IR upregulated mechanisms, which may account for their clinical response among TNF-IR IBD patients.